Here is a quick summary: 1) Coordinate investment in key R&D areas to further societal goals
2)Foster a biological data ecosystem, while adhering to principles of security, privacy, and responsible conduct of research
5) Expand market opportunities for #bioenergy and #biobased products and services 6) Ensure sufficient #talent and a next generation of leaders to advance the field
7) Clarify and streamline regulations to support the safe use of products of #biotechnology 8) Elevate biological risk management - via #biosecurity and #biosafety innovation
9) Establish and develop systems to assess and growth the #bioeconomy 10) Secure and protect the US bioeconomy by establishing monitoring solutions 11) Engage the international community to develop the bioeconomy
The initial draft looks rather promising and the push to develop and support the #bioeconomy, #biomanufacturing and #biotechnology is likely to bring the next wave of growth.
An Israeli biotech company, Renewal Bio that recently created mouse embryos using stem cells, has announced plans to make human embryos to harvest tissue for organ transplants and anti-aging procedures.
The scientist behind the work clarified that:
The synthetic embryos were not "real" embryos and did not have the potential to develop into live animals. But that is partly because they don't have the technology, right now, to do so.
He admits to taking his "ground-breaking" technology to the next level and creating human embryos. The purpose is to harvest tissue to be used in transplant treatments meant to lengthen a person's life and health.
At both dose levels, $NTLA-2001 was generally well tolerated. 2 patients reported transient infusion reactions, which was the only observed treatment-related adverse event.
$NTLA-2001 is an in-vivo administered #genetherapy.
It is one of the first few in-vivo #GeneTherapy being tested. Congrats to the $NTLA and $REGN teams.